Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
In this double blind randomised controlled pilot trial the investigators aim to determine the efficacy of minocycline as an adjunct to treatment as usual in patients with major depressive disorder. The investigators hypothesize that the multiple neuroprotective effects of minocycline will lead to an improvement in depressive symptoms in participants that were given minocycline plus treatment as usual
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
patients aged 18-65 years
Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of major depressive disorder
competent and willing to give informed consent
taking the current antidepressant medication for a minimum of 4 weeks prior to baseline
the current episode of depression has failed to remit with at least two courses of antidepressant treatment (one of which is the current course)
able to take oral medication
if female, willing to use adequate contraceptive precautions and to have monthly pregnancy tests.
relevant medical illness (renal, hepatic, cardiac, serious dermatological disorders such as exfoliative dermatitis, systemic lupus erythematosis)
prior history of intolerance to any of the tetracyclines
concomitant penicillin therapy
concomitant anticoagulant therapy
presence of a seizure disorder
currently taking valproic acid
any change of psychotropic medications within the previous 4 weeks
diagnosis of substance abuse (except nicotine or caffeine) or dependence within the last 3 months according to DSM-IV criteria